Last reviewed · How we verify
ERA as specific PAH treatment
Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension.
Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | ERA as specific PAH treatment |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Endothelin receptor antagonist |
| Target | Endothelin receptor (ETA/ETB) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
ERAs inhibit the binding of endothelin-1 to endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells and endothelial cells. Endothelin-1 is a potent vasoconstrictor and mitogen implicated in PAH pathophysiology. By antagonizing these receptors, ERAs reduce pulmonary vascular resistance, improve right ventricular function, and delay disease progression in PAH patients.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Nasal congestion
- Hepatotoxicity
Key clinical trials
- Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (PHASE3)
- TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
- Endothelial Function in Patients With Pulmonary Arterial Hypertension (NA)
- A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERA as specific PAH treatment CI brief — competitive landscape report
- ERA as specific PAH treatment updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI